Symposium at UC San Diego goes over latest scientific evidence about medical uses of pot
The
topic of marijuana got a serious scientific treatment Wednesday at the
University of California San Diego, where researchers outlined the
latest evidence about the drug.
The
federal government estimates that 22.2 million Americans use cannabis
today, an increase of about 4.4 million since 2002. The rise comes amid a
growing medical marijuana movement that has culminated with full
legalization in Colorado, Alaska, Oregon, Washington state and
Washington, D.C.
California could join those ranks in November if the state’s voters approve marijuana for recreational use.
Science
is trying to catch up with the public’s growing acceptance and use of a
plant that contains 400 chemical compounds, including more than 60
cannabinoids known to act directly on specialized receptors in the
brain.
Understanding
just how these compounds work — how they influence issues such as
addiction, pain relief and even control of severe childhood seizures —
is an evolving effort.
Wednesday’s symposium started with a presentation on marijuana’s prenatal impact.
The
speaker was Larry Parsons, a member of the Committee on the
Neurobiology of Addictive Behavior at The Scripps Research Institute in
La Jolla. Parsons explained that THC, a cannabinoid that gives marijuana
its psychotropic effects, clearly affects brain development before
birth and can cause lasting effects into adulthood.
Research
on mice and observation in humans have shown that THC influences neuron
development and signaling, potentially increasing the risk of memory
problems, addiction and perhaps schizophrenia later in life.
Also
weighing in was Christina Chambers, director of the Center for Life
Course Research, part of UC San Diego’s Clinical and Translational
Research Institute.
She
said studies of children whose mothers used marijuana during pregnancy
suggest that the drug elevates the risk of hyperactivity, attention
deficit disorder, lack of motor coordination and poor academic
achievement during the first two decades or so of life.
However,
all of these results came from relatively small studies — and many of
those studies are decades old. Larger, newer clinical trials are
necessary to prove marijuana’s imprint on childhood development.
“The sample sizes are so small. There is a critical need for more data,” Chambers said.
As
it happens, UC San Diego is in the thick of a massive research project
that is expected to yield unprecedented insight into how the adolescent
mind is affected by marijuana and many other factors.
The
university is coordinating the Adolescent Brain Cognitive Development
Study, which is tracking 10,000 children across the nation for a decade.
Annual
testing, which will include highly sensitive brain imaging, is expected
to help researchers map how life events of all kinds shape brain
development.
“To be able to study kids longitudinally, starting at age 9 and 10, is going to transform our understanding,” Chambers said.
Adults also got attention during Wednesday’s event.
Researchers
said studies indicate that medical marijuana is most effective at
fighting muscle spasms caused by multiple sclerosis and at combating the
neuropathic pain that cancer patients often suffer.
There
is also evidence, though less robust, of cannabis’ effects on nausea
caused by chemotherapy, in promoting weight gain for HIV-infected
patients and in easing sleep disorders.
On the flip side, cannabis can cause nausea, dizziness, impaired driving, addiction and a reduction in cognition.
Meanwhile, the cognitive effects of marijuana are thought to be less severe in adults than in children and adolescents.
Scientists
continue trying to determine the proper dosing for conditions where
marijuana shows promise. Sometimes, the right answer can be a bit
counter-intuitive.
For
example: Dr. Barth Wilsey, an associate physician of psychiatry at UC
San Diego, cited research that shows marijuana with a THC concentration
of only 1.3 percent is just as effective at controlling neuropathic pain
as varieties with more than twice the potency.
“You don’t need a very high concentration to bring about relief,” Wilsey said.
One
topic concerning children that did not get much attention Wednesday was
the increasing use of low-THC hemp oil to treat epileptic seizures.
Media
coverage and social-media stories of sometimes-miraculous decreases in
seizure activity for some kids treated with the oil has prompted many
states to legalize its use.
But more recent studies have found, again in small numbers of children, that the oil is not a panacea.
Dr.
Kevin Chapman, who works in the pediatrics department at Children’s
Hospital Colorado, co-authored a 2015 study showing that only a third of
75 kids in his state treated with cannabis oil saw a 50 percent or
greater reduction in seizures.
And
researchers discovered that 44 percent of the test subjects suffered
adverse events, including an increase in seizures for 13 percent of the
participants.
This
observational study has limited value because it did not control for
factors such as the children using different doses and types of hemp
oil, Chapman said Wednesday in a phone interview.
He
noted that British drug company GW Pharmaceuticals is about to release
results of the world’s first double-blind, placebo-controlled study of
cannabidiol compounds in children with a rare form of epilepsy.
Seen
as the gold standard of medical research, this type of clinical trial
should shed brighter light on the question of just how much marijuana
might help or hurt kids suffering from seizures, Chapman said.
Until
the debate is fully settled in scientific circles, he advised families
to use high-cannabidiol hemp oil, often called CBD, as a last resort.
No comments:
Post a Comment